Recombinant Human GIPR N-ECD (C-6His)

Description

EnkiLife provides the Recombinant Human GIPR N-ECD (C-6His) protein,aslo know as Gastric inhibitory polypeptide receptor,GIP-R,Glucose-dependent insulinotropic polypeptide receptor,GIPR, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Gastric inhibitory polypeptide receptor is produced by our Mammalian expression system and the target gene encoding Arg22-Gln138 is expressed with a 6His tag at C-terminus.Accession:P48546. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:14.3 KDa. Background:GIP receptor (GIPR) belongs to the G-protein coupled receptor family, activating adenylate cyclase and increasing levels of intracellular cyclic adenosine monophosphate (cAMP) in pancreatic b cells, thereby stimulating insulin section glucosedependently. New discoveries of GIP receptor (GIPR) biology in adipose tissue, as well as findings that co-agonists for the glucagon-like peptide-1 receptor (GLP-1R) and GIPR induce greater weight loss than that seen with GLP-1R agonists alone, has led to continued interest in manipulating GIPR activity for the treatment of obesity/type 2 diabetes mellitus (T2DM).